Caregen Co., Ltd. Overview
Caregen is a Korean, founder-controlled, export-oriented developer and manufacturer of synthetic biomimetic peptides and recombinant growth factors. Its commercial base is a high-margin portfolio of peptide-enhanced dermal fillers, mesotherapy products and cosmeceuticals sold through exclusive or non-exclusive distributors in roughly 130 countries, with exports historically around 95–98% of revenue. Since 2022 it has used the same peptide library to build an oral "metabolic health" franchise — ProGsterol (glucose), MyoKi (muscle) and Korglutide (a GLP-1/IGF-1 dual-acting weight-management peptide) — registered as dietary ingredients via US FDA NDI notifications rather than as drugs. A drug pipeline led by CG-P5, a topical peptide eye drop for wet AMD that completed a US Phase 1 study, provides option value. The investment case has swung sharply in 2025–26: record contract announcements and a KRW 7.7tn peak valuation have been followed by earnings dilution, Middle East receivable write-downs, contract terminations and a 75%+ share-price decline.
Company's own description (Q3 FY2024 quarterly report, paraphrased)
Caregen describes itself as a company that, based on research into biomimetic peptides and growth factor proteins, develops and sells pharmaceuticals, health functional foods, medical devices and cosmetics. Peptides are produced by chemical synthesis at scale; growth factors are produced by genetic engineering. The company states it has built a peptide library protected by more than 730 registered domestic and overseas patents (Sep 2024), and sells "professional therapy" products (fillers, mesotherapy) and functional cosmetics incorporating its peptides, dual-encapsulation and sustained-release technologies in about 130 countries. It describes its planned new businesses as antiviral (COVID-19) medicines, macular-degeneration medicines, and animal medicines and functional feed. The company notes it started in 2001 developing protein chips for cancer diagnosis, pivoted from 2003 to growth factors and biomimetic peptides for devices and cosmeceuticals, and from 2022 entered health functional foods.
Independent characterisation
Business model: Vertically integrated peptide platform — discovery (library of 1,200+ proprietary peptides per the company's BIO USA profile), in-house synthesis (Hwaseong peptide plant, 10 tonnes/year design capacity), finished-goods manufacture (Gunpo plants 1 and 2), and B2B export to country distributors. Distribution partners typically bear local registration costs and timelines (Dealsite, 2023 company interview).
Revenue model: Overwhelmingly product sales (devices, cosmeceuticals, dietary supplements, bulk ingredients). Licensing revenue: none disclosed. The Q3 FY2024 report states the company had no licence-out, licence-in or technology-alliance contracts. Long-term "supply agreements" announced in the press are frequently framework or non-binding agreements whose value depends on partner orders — a structural feature that has repeatedly produced gaps between headline contract values and booked revenue.
Value-chain position: Upstream (API/ingredient) through finished product; no direct-to-consumer retail of note; no domestic Korean sales of the peptide supplements (the company has said Korean regulators do not recognise synthetic peptides as health-food ingredients — Dealsite, Aug 2025).
Customers: Country distributors, aesthetic clinics (indirectly), pharmaceutical and nutraceutical distributors (e.g., IFA Celtics Mexico, Atabay Türkiye, Li Shizhen Pharmaceutical China, 2San USA), and cosmetics brand owners for raw peptides (e.g., BASF supply agreement, 2020).
End-markets: Medical aesthetics (fillers, mesotherapy, hair-loss), cosmeceuticals, dietary supplements (glycaemic control, weight management, sarcopenia), and, prospectively, ophthalmology (wet AMD, dry eye) and drug delivery (Luxidase platform).
Strategy
Stated strategic themes (management statements, paraphrased)
Peptide platform expansion: Grow from aesthetics into supplements, pharmaceuticals and delivery platforms, leveraging a large unpatented reserve of protein/peptide candidates (company statement, Jul 2025: more than 1,200 unpatented candidates).
"Metabolic health portfolio": Korglutide (weight), MyoKi (muscle), ProGsterol (glucose) marketed as a bundle through one partner per country, with partners funding registration.
US mainstream retail entry: via 2San, positioning FDA NDI-notified synthetic peptides as a compliant alternative to grey-market research peptides.
Transition toward a drug developer: CG-P5 licensing/co-development, CG-T1, an oral obesity drug (clinic entry targeted end-2026), and Luxidase licensing.
2026 framed by the CEO as the turning point: where global sales begin in earnest (Venturesquare, May 2026).
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| Korglutide global out-supply campaign | Jul 2025 – Feb 2026 | Mexico, Canada, Thailand, Türkiye, Brazil, China contracts; Lebanon and Mexico registrations; US NDI |
| Dividend policy | Feb 2025 | Two dividends per year; consolidated payout of at least 30% for three years (Smart Today, Feb 2025) |
| Value-up plan / treasury-share use | Mar 2026 | Articles amended; plan to sell 383,577 treasury shares (base price KRW 130,352, ~KRW 50bn) in H1 2026 to fund CG-P5/CG-T1 trials. Not executed; at KRW 43,750 the block would raise only c. KRW 16.8bn and management said it would not enlarge the sale (Dealsite, Sep 2026) |
| R&D commitment | Ongoing | Q3 FY2024 report commits to at least 5% of revenue on R&D; H1 FY2026 ratio 5.14% |
| Luxidase / Hyalux launch | Feb–Apr 2026 | Delivery-platform commercialisation and licensing outreach (Estée Lauder visited the EURETINA/CPHI Milan booth in Oct 2026 per Finance Scope) |
| BD partnering | Jun 2026 | BIO USA 2026: pre-arranged meetings with 25+ companies incl. Eli Lilly, AbbVie, Bayer, Daiichi Sankyo, Santen |
| ESG / sustainability commitments | — | — |
| Cost programmes | 2,025 | Management cited peptide production efficiency and R&D cost optimisation (Q3 FY2025 commentary); no quantified target |
Medium-term targets and guidance record
No current quantified revenue or margin guidance: was found for FY2026.
Guidance credibility record: FY2023 guidance of KRW 150bn (incl. KRW 70–80bn ProGsterol) cut to KRW 80bn in Dec 2023 (actual KRW 79.2bn); a 2025 target of KRW 100bn+ in supplement revenue (Dealsite, Aug 2025) compares with actual FY2025 supplement revenue of KRW 5.6bn.
Products & Services
Professional therapy (medical devices: fillers, mesotherapy) — exported
| Brand / product | Description | Target customer | Notes |
|---|---|---|---|
| Revofil (incl. Fine, Aquashine, Aquashine BTx, Aquashine Platinum / BR Platinum, Ultra) | Peptide-containing hyaluronic-acid fillers and skin boosters; Aquashine BTx positioned as "botulinum-like" peptide filler | Aesthetic clinics via distributors | CE marks 2011–2019; Revofil Ultra domestic clinical trial plan approved by MFDS (2023) |
| Prostrolane; Prostrolane B-Series (Inner B, Natural B, Blanc B, Inner BSE) | Face/body/obesity injectable mesotherapy and fillers | Clinics | CE 2015, 2017, 2018 |
| CG Dimono PTx | Peptide-based dermal filler with "immediate effect"; renewed formulation presented at IMCAS Jan 2026 | Clinics | CE Apr 2023; core of 2024 Middle East three-country supply announcement |
| CG Styler 600 | Body-contouring injectable | Clinics | CE May 2020 |
| Dr.CYJ (Hair Filler) | Peptide injectable for hair-loss improvement | Clinics | CE Mar 2016; UK MHRA registration May 2023 |
| Dermaheal (mesotherapy solutions incl. HL, SB) | Face and hair mesotherapy | Clinics | First CE 2009 |
| Intracisc / Linevisc | Joint fillers | Clinics | CE Dec 2018 |
Pricing: not publicly disclosed.
Cosmeceuticals
| Brand | Description |
|---|---|
| Dermaheal | Peptide/growth-factor skincare (anti-wrinkle, regeneration) |
| Purilux | Whitening |
| Pim-Pim-Paul | Anti-inflammatory/acne |
| PTx | Home-care "botulinum-like" anti-wrinkle line |
| Dr.CYJ iDR / pDR | Damaged-hair repair (CG-Follicare "hair bond repairing" peptide; company-reported clinical repair within 5 minutes lasting 7 days) |
| Pelo Baum / Pelo Baum Plus | Hair-loss shampoos, conditioners, revitalising solution (MFDS functional cosmetic registration Jul 2023) |
| Renokin | Scalp care (listed by Simply Wall St company description) |
| Neovert | Skincare (listed by Simply Wall St company description) |
Health functional foods / dietary supplements
| Product | Ingredient / mechanism (company-described) | Regulatory status | Key commercial events |
|---|---|---|---|
| ProGsterol | Deglusterol: synthetic peptide improving insulin-receptor sensitivity; glucose management for type 2 diabetes/pre-diabetes | US FDA NDI (Mar 2022); Philippines FDA (2020/2023); Halal (2023); EU novel food application in final stage (May 2026) | Iran launch with physician prescribing (May 2024); Pakistan approval (May 2024); Farmabol Poland USD 5.7m/3 years (May 2026) |
| MyoKi | Myostatin-inhibiting peptide for muscle mass | US FDA NDI; India registration | IFA Celtics Mexico USD 33.29m/5 years (Aug 2025). Company-reported 12-week sarcopenia study: limb muscle +2.52%, grip strength +5.2–6.2% |
| Korglutide | Seven-amino-acid oral peptide described as GLP-1R/IGF-1R dual-acting; one daily sachet | US FDA NDI (30 Jan 2026); Lebanon registration (Jul 2025); Mexico COFEPRIS registration as "Trimtide" (Feb 2026); Thai registration filed (2025) | India 100-patient, 12-week study: mean weight loss 10.78%, ~72% of loss as fat, muscle loss 0.27 kg (company-reported); second 200-subject study in normal-BMI/high-body-fat adults |
Raw materials (B2B ingredients)
About 20 growth factors (e.g., CG-EGF) and around 300 peptides (e.g., CG-Purilux) and mixtures sold under the Caregen name; exclusive supply of four patented peptides to BASF since 2021 (Q3 FY2024 report).
Pipeline / platform technologies (pre-commercial)
| Asset | Indication / use | Stage (latest public) |
|---|---|---|
| CG-P5 | Wet AMD; topical VEGFR2-inhibiting peptide eye drop | US Phase 1 completed (NCT06132035); results presented at Retina World Congress 2026, ASRS (Jul 2026) and EURETINA (Oct 2026); Phase 2 planned (incl. Eylea combination and dry AMD) |
| CG-P5 (dry AMD) | Geographic atrophy / dry AMD | Preclinical completed |
| Diabetic retinopathy (CG-P5 mechanism) | DR | Preclinical completed |
| CG-T1 | Dry eye; PAC1R activation, anti-inflammatory eye drop | Preclinical |
| SpikeDown | COVID-19 / pulmonary fibrosis; nasal spray | Phase 1 completed (Israel, Aug 2023) |
| Oral obesity drug (unnamed) | Obesity (drug, not supplement) | Animal studies completed; clinical entry targeted end-2026 (CEO, Aug 2025) |
| Hyperhidrosis peptide | Hyperhidrosis | Human application study completed |
| Hyalux | Ten-amino-acid peptide mimicking hyaluronidase | Cosmetic commercialisation targeted 2026 (CEO, Feb 2026) |
| Luxidase | Topical drug/ingredient delivery platform (company claims 4–5x skin permeation) | Unveiled at in-cosmetics Global, Apr 2026; licensing discussions |
| Animal health peptides | Feline peritonitis, pet allergy | Research |
Financial Narrative
Income statement (consolidated)
Sources: OpenDART via Bullstory and Butler (FY2021–FY2025). FY2021 growth derived against FY2020 revenue of KRW 60.3bn (company release, Mar 2021). Revenue CAGR FY2021–FY2025: 5.4% (derived).
Additional FY2025 detail (OpenDART via Simply Wall St and ValueLine): cost of revenue KRW 20.6bn, gross profit KRW 52.2bn (gross margin 71.7%), SG&A KRW 31.8bn (up 51.1% YoY), of which bad-debt expense KRW 12.0bn (FY2024: KRW 0.5bn). Pre-tax income KRW 22.4bn; tax KRW 2.3bn. EBITDA KRW 27.1bn (ValueLine), EBITDA margin 37.2%.
Per-share data
FY2022–FY2023: Q3 FY2024 report (split-adjusted). FY2025: ValueLine. FY2024: derived (net income / c. 48.95m weighted shares) — not company-reported.
Year-end dividend per share
Interim dividends (paid each July) were c. FY2026 interim: KRW 200/share (KRW 9.77bn), declared 3 Jul 2026.
Quarterly run-rate (consolidated, preliminary/fair-disclosure basis)
Q1 FY2025–Q1 FY2026: DART preliminary results (StockHub summary; Smart Today for Q3 FY2025). Q2 FY2026 is derived from ValueLine trailing-twelve-month (TTM) figures at Mar-2026 and Jun-2026 (revenue TTM KRW 74.89bn; operating income TTM KRW 18.24bn; net income TTM KRW 22.87bn); no preliminary Q2 FY2026 release was found. Derived H1 FY2026: revenue c. KRW 41.5bn (+5% YoY), operating income c. KRW 15.4bn, net income c. KRW 16.0bn.
Balance sheet (consolidated)
Sources: Q3 FY2024 report (FY2022–FY2023); ValueLine/OpenDART (FY2024–FY2025). Liquid assets FY2024–FY2025 reconcile to Dealsite (Apr 2026: KRW 44.3bn → KRW 29.1bn). Net debt excludes lease liabilities (not separately verified). FY2025 totals (assets KRW 231.3bn, liabilities KRW 18.8bn, equity KRW 212.5bn) confirmed by Kormedi (Aug 2026).
30 June 2026 (H1 FY2026, ValueLine): total assets KRW 241.3bn; cash KRW 5.9bn; current FVPL assets KRW 29.7bn (liquidity c. KRW 35.6bn); receivables KRW 30.8bn; inventories KRW 23.8bn; PP&E KRW 124.5bn; liabilities KRW 22.6bn; equity KRW 218.7bn; no borrowings.
Cash flow
Source: OpenDART via Bullstory. The negative FY2022 figure is as reported by the aggregator and likely reflects classification of financial-asset movements; not independently reconciled.
FY2023 and FY2024 dividends from Q3 reports (no Q4 payments); FY2025 from ValueLine. FY2024 buyback derived from the change in treasury stock (KRW 67.2bn → KRW 72.2bn; 263,451 shares acquired Sep–Oct 2024).
FY2025 capital expenditure (ValueLine): PP&E KRW 3.9bn plus intangibles KRW 1.1bn; free cash flow c. KRW 13.7bn (derived: OCF minus capex and intangibles). FY2024 capex was dominated by the Daechi-dong building: PP&E additions of KRW 65.8bn in 9M FY2024 alone. TTM to Jun-2026: OCF KRW 26.1bn, capex KRW 4.7bn, FCF c. KRW 21.4bn, dividends paid KRW 21.4bn.
Key ratios (derived, ending-balance basis)
-
Inventory turnover (Dealsite, company-basis): 1.48x FY2024, 1.01x FY2025.
-
Interest coverage and net debt/EBITDA: not meaningful (no borrowings; net cash).
-
ROIC: not computed (invested-capital basis not disclosed; with almost no debt, ROE is the operative return measure).
-
Cash conversion cycle: not computable on a consistent basis; the DSO deterioration is the material signal.
-
ValueLine-reported TTM ROE at Jun-2026: 10.46%.
Commentary on trends, inflections and drivers
-
Growth stalled after FY2023. Revenue compounded 16–17% in FY2022–FY2023 (ProGsterol launch), slowed to 4% in FY2024 and contracted 11.8% in FY2025. Management attributes FY2025 to the CG-DIMONO PTX renewal, deliberate supply restraint to the Middle East, delayed partner registrations of supplements and deferral of some revenue into 2026 (Dealsite, Apr 2026).
-
Margin compression is partly non-cash. Operating margin fell from 51.0% (FY2023) to 28.0% (FY2025). Of the KRW 13.9bn decline in operating income in FY2025, the KRW 11.5bn increase in bad-debt expense explains most of it: the company provisioned receivables from Iran and other Middle East customers as the regional war looked likely to persist; credit-impaired receivables overdue more than six months reached c. KRW 17.8bn and cumulative impairment rose from KRW 0.6bn to KRW 12.6bn (Dealsite, Apr 2026). Gross margin remained above 70%.
-
Working-capital quality has deteriorated. Receivables rose from KRW 7.0bn (FY2022) to KRW 30–33bn (FY2024–FY2025) while revenue grew only 5%, pushing DSO from c. 37 to c. 150 days. Inventories rose 25% in FY2025 (products +21.7%, raw materials +51.9%), which the company describes as pre-stocking for 2026.
-
The cash buffer has been spent. Liquid financial assets fell from KRW 140.5bn (FY2022) to KRW 29.0bn (FY2025) as the company bought a Seoul building (c. KRW 65bn, debt-free) and paid dividends exceeding earnings (FY2025 payout 106.3%). The balance sheet remains unlevered, but optionality to fund Phase 2 trials internally is materially lower than two years ago.
-
Early-2026 recovery is uneven. Q1 FY2026 revenue of KRW 22.7bn was a record quarter at a 45% margin; derived Q2 FY2026 operating income of c. KRW 5.2bn suggests additional bad-debt charges (TTM bad-debt expense rose from KRW 12.0bn to KRW 14.7bn by June 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Location | Activity | Ownership | Status |
|---|---|---|---|---|
Caregen Co., Ltd. | Korea | Parent; all operating activity | — | Operating |
Caregen Biopharma Inc. | USA (Chicago) | Medical/pharmaceutical R&D | 100% | Assets KRW 37m at end-FY2024; zero assets, revenue and net result reported for FY2025 and 2026 YTD (Dealsite, Sep 2026) — effectively dormant |
Zhe Jiang Ke Yi Kai Jian Sheng Wu Ke Ji Co., Ltd. | China | Cosmetics wholesale/retail | 49% (associate) | Loss-making; FY2025 revenue KRW 4.7bn, net loss KRW 0.2bn, liabilities KRW 9.2bn vs assets KRW 2.1bn (capital impairment) — Dealsite, Apr 2026 |
Zhe Jiang Dayimei Health Technology Co., Ltd. | China | Cosmetics wholesale/retail | 6.67% (associate via board seat) | Carried at nil |
CYJ International Company Ltd. | Hong Kong | JV | 35% | Liquidated by 30 Sep 2024 |
CYJ International Taiwan Inc. | Taiwan | Equity investment | Minority | Carried at cost KRW 0.3bn |
Revenue by Segment
| Product group | FY2022 | FY2023 |
|---|---|---|
Professional therapy total (KRW Bn) | 53.65 | 54.44 |
Professional therapy - face (KRW Bn) | 32.69 | 31.28 |
Professional therapy - hair (KRW Bn) | 14.39 | 15.20 |
Professional therapy - body (KRW Bn) | 5.44 | 7.40 |
Professional therapy - joint (KRW Bn) | 0.93 | 0.56 |
Cosmeceuticals (KRW Bn) | 11.99 | 10.89 |
Raw materials - peptides and growth factors (KRW Bn) | 4.32 | 3.09 |
Health functional foods (KRW Bn) | 0.21 | 12.20 |
Other and accounting adjustments (KRW Bn) | -1.07 | -1.42 |
Total revenue (KRW Bn) | 69.10 | 79.21 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%)
| Product group | FY2022 | FY2023 |
|---|---|---|
Professional therapy (%) | 77.6 | 68.7 |
Cosmeceuticals (%) | 17.3 | 13.8 |
Raw materials (%) | 6.2 | 3.9 |
Health functional foods (%) | 0.3 | 15.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (FY2022–FY2025)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Health functional food revenue (KRW Bn) | 0.21 | 12.20 | 12.61 | 5.60 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 59.1 | 69.1 | 79.2 | 82.6 | 72.8 |
Operating income (KRW Bn) | 28.2 | 33.6 | 40.4 | 34.2 | 20.4 |
Net income (KRW Bn) | 25.2 | 27.2 | 39.9 | 32.3 | 20.1 |
Operating margin (%) | 47.7 | 48.6 | 51.0 | 41.4 | 28.0 |
Net margin (%) | 42.6 | 39.4 | 50.4 | 39.1 | 27.6 |
Revenue growth YoY (%) | -2.0 | 16.9 | 14.6 | 4.3 | -11.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Basic EPS (KRW) | 556 | 813 | 660 | 374 |
Diluted EPS (KRW) | 556 | 813 | 660 | 374 |
Per-Share Data (FY2023–FY2025)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Year-end DPS (KRW) | 400 | 400 | 200 |
Income Statement
| Metric | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 |
|---|---|---|---|---|---|---|
Revenue (KRW Bn) | 21.3 | 18.1 | 17.1 | 16.3 | 22.7 | 18.8 |
Operating income (KRW Bn) | 10.2 | 7.4 | 9.9 | -7.1 | 10.2 | 5.2 |
Net income (KRW Bn) | 8.4 | 4.8 | 10.2 | -3.3 | 11.7 | 4.3 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (KRW Bn) | 234.1 | 247.3 | 240.7 | 231.3 |
Cash and cash equivalents (KRW Bn) | 5.2 | 31.5 | 5.1 | 8.9 |
Short-term financial instruments (KRW Bn) | 71.4 | 80.9 | 0.0 | 0.0 |
Current FVPL financial assets (KRW Bn) | 63.9 | 20.3 | 39.2 | 20.2 |
Total liquid financial assets (KRW Bn) | 140.5 | 132.7 | 44.3 | 29.0 |
Trade receivables, net (KRW Bn) | 7.0 | 13.1 | 33.0 | 30.0 |
Inventories (KRW Bn) | 10.3 | 18.7 | 18.1 | 22.6 |
Property, plant and equipment (KRW Bn) | 60.4 | 64.0 | 125.6 | 125.4 |
Intangible assets (KRW Bn) | 3.9 | 4.7 | 5.0 | 5.1 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 |
Short-term borrowings (KRW Bn) | 0 | 0 | 0 | 0 |
Long-term borrowings (KRW Bn) | 0 | 0 | 0 | 0 |
Net debt (KRW Bn) | -140.5 | -132.7 | -44.3 | -29.0 |
Total liabilities (KRW Bn) | 18.1 | 20.0 | 17.7 | 18.8 |
Total equity (KRW Bn) | 216.0 | 227.3 | 223.0 | 212.5 |
Current assets (KRW Bn) | 158.9 | 166.4 | 96.4 | 83.1 |
Current liabilities (KRW Bn) | 10.5 | 11.3 | 8.1 | 8.4 |
Working capital (KRW Bn) | 148.4 | 155.1 | 88.3 | 74.8 |
Treasury stock at cost (KRW Bn) | 67.3 | 67.2 | 72.2 | 72.2 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | 51.9 | -27.7 | 28.6 | 13.5 | 18.6 |
Dividends & Capital Returns
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Cash dividends paid (KRW Bn) | 28.5 | 31.4 | 31.1 |
Share buybacks (KRW Bn) | 0.0 | 5.0 | 0.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE (%) | 12.6 | 17.6 | 14.5 | 9.5 |
ROA (%) | 11.6 | 16.1 | 13.4 | 8.7 |
Current ratio (x) | 15.2 | 14.7 | 12.0 | 9.9 |
Total liabilities to equity (%) | 8.4 | 8.8 | 7.9 | 8.8 |
Debt to equity (%) | 0 | 0 | 0 | 0 |
Asset turnover (x) | 0.30 | 0.32 | 0.34 | 0.31 |
Days sales outstanding (days) | 37 | 61 | 146 | 150 |
Revenue by Region
| Region | FY2024 | FY2025 |
|---|---|---|
Asia incl. Middle East (KRW Bn) | 49.2 | 32.4 |
Rest of world (KRW Bn) | 33.4 | 40.4 |
Total (KRW Bn) | 82.6 | 72.8 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 27,420 | 27,500 | 28,800 | 71,800 |
Year-end market cap (KRW Bn) | 1,473 | 1,477 | 1,547 | 3,857 |
Valuation Multiples
| Multiple | Caregen | Basis / source |
|---|---|---|
P/E (TTM) | 87.4x | ValueLine |
P/B | 9.14x | ValueLine |
EV/Sales (TTM) | c. 26x | Derived: EV ≈ KRW 1,962bn (market cap less c. KRW 35.6bn liquid assets at Jun 2026) / TTM revenue KRW 74.9bn |
EV/EBITDA (TTM) | c. 62x | Derived: EV / TTM EBITDA KRW 31.4bn (ValueLine) |
Dividend yield | 1.08% | Butler |
Peer reference | Classys P/E 15.0x (Butler, Oct 2026); Hugel FY2026E P/E 18.9x and Pharma Research 15.9x (Alphadistill, 2026) | Mixed dates/bases |
Analyst Conclusions
Guidance and expectations
-
Management qualitative guidance: global sales to accelerate from Q2 FY2026, led by North and Latin America; 2026 described as a turning point (May 2026). No numeric FY2026 guidance.
-
Consensus growth expectations: not publicly disclosed (no consensus); Investing.com notes analysts expect revenue growth this year (unquantified).
-
Run-rate check: derived H1 FY2026 revenue c. KRW 41.5bn (+5% YoY) and OP c. KRW 15.4bn (margin c. 37%) imply a FY2026 revenue trajectory of roughly KRW 80–85bn absent a step-change in H2 — a dossier extrapolation, not guidance.
Bull case (grounded in the data above)
-
Supplements go mainstream in the US and China. NDI status plus 2San's pharmacy access and Li Shizhen's e-commerce launch could convert a small share of KRW 1.1tn+ of headline contract value into revenue at 70%+ gross margins, using already-installed capacity (peptide utilisation below 25%).
-
CG-P5 licensing. Phase 1 data superior to aflibercept on IRF clearance in a 45-patient study, plus 25+ big-pharma meetings, could yield an upfront/milestone deal that re-rates the company as a drug developer.
-
Earnings normalisation. FY2025 was depressed by a KRW 12.0bn non-cash provision; Q1 FY2026 already produced a 45% margin. Any recovery of Middle East receivables would reverse charges.
Bear case
-
Contract-conversion failure is structural, not cyclical. RONESCA (1.2% in nine years), the 2016 terminations and the FY2023/FY2025 guidance misses suggest headline values systematically overstate economic substance.
-
Valuation remains demanding after the crash. At c. 87x TTM earnings and c. 26x EV/Sales, the shares price in success that FY2025–H1 FY2026 numbers do not yet show; Korean aesthetic peers with faster growth trade at 15–19x P/E.
-
Funding and governance constraints. Liquid assets of c. KRW 29–36bn, dividends exceeding earnings, a failed treasury-sale plan, falling R&D and repeat disclosure sanctions limit the capacity to fund Phase 2 internally and sustain a governance discount.
Catalysts and monitorables (next 12 months)
| Item | Timing | What to watch |
|---|---|---|
| Q3 FY2026 results | 6 Nov 2026 | Supplement revenue, bad-debt charges, receivable collection |
| FY2026 results and dividend | Feb–Mar 2027 | Whether payout again exceeds earnings |
| CG-P5 partnering / Phase 2 start | Ongoing | Any licence, upfront size, Phase 2 IND |
| Oral obesity drug clinical entry | End-2026 target | IND/CTA filing |
| Li Shizhen sell-through | Quarterly | Order flow vs c. KRW 111bn/yr implied run-rate |
| US 2San retail listings | H2 2026 | Confirmed shelf placements at named chains |
| EU novel-food decision (Deglusterol) | 2026–27 | Authorisation |
| RONESCA contract expiry | Jul 2027 | Renewal, termination or write-off |
| Treasury-share cancellation deadline | c. 2027 | Cancellation vs disposal |
| KRX penalty points | Ongoing | Any further designations |
| Middle East normalisation | Ongoing | Resumption of Iran/Gulf shipments |
Analyst verdict
Caregen is a genuinely differentiated peptide manufacturer with an unusually profitable core, but it is not — on the evidence of the past three years — a reliable compounder. The company's audited numbers tell a sober story: revenue has grown at only 5.4% a year since FY2021, operating income has halved from its FY2023 peak, receivables have quadrupled, and the cash cushion that once covered two years of revenue has shrunk to under five months of sales after a property purchase and dividends paid out of retained earnings. Against that, the headline narrative — more than KRW 1.1tn of supply agreements, US NDI status, a 45-patient CG-P5 study that outperformed Eylea on fluid clearance — remains largely unconverted into revenue or licensing cash.
The 76% share-price collapse since February 2026 has removed much of the speculative premium, yet the stock still trades at roughly 87x trailing earnings and about 9x book, multiples that require either a step-change in supplement sell-through or a validated CG-P5 partnership. Both are plausible; neither is evidenced. The governance overlay — founder control near 65%, recurring disclosure sanctions, an audit disclaimer in recent memory and an R&D budget moving opposite to the drug-developer pitch — warrants a persistent discount.
Our synthesis: Caregen is an option-rich but execution-poor asset. The two variables that matter most are measurable within twelve months — quarterly supplement revenue (did Q2 FY2026's 29% share hold and grow?) and a signed, value-disclosed CG-P5 licence. Until either appears, earnings quality (bad-debt trends, DSO, payout above 100%) is the more reliable guide than contract announcements.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Compensation |
|---|---|---|---|---|
Chung Yong-ji (정용지) | Founder, CEO, Representative Director; also leads research | Since Aug 2001 | Born 25 Feb 1970; BS Genetic Engineering, Sungkyunkwan University; MS Biology, University of Texas at San Antonio; PhD Animal Science, Cornell (Wikipedia: 1996; company filing: 2000 — discrepancy); postdoctoral research, Northwestern University Feinberg School of Medicine (2000–2001) | FY2025 salary KRW 1.675bn (Dealsite, Apr 2026); estimated c. KRW 14bn in FY2025 dividends; FY2019 pay KRW 1.0bn |
Kim Eun-mi (김은미) | Vice President, inside director; R&D management (vice-head of central research institute) | Joined 2003; director 2014–2019; VP since 2020; re-elected inside director Mar 2024 | MSc Immunology, Hanyang University (2007) | Not publicly disclosed for FY2025 |
Ra Hee-sook (라희숙) | Vice President (signatory officer for periodic reports) | — | — | — |
Jeong Tae-jin (정태진) | CFO (as quoted in Oct 2018) | — | — | — |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Shares | % of issued | Date / source |
|---|---|---|---|
Chung Yong-ji | 34,011,291 | 63.31 | 29 Jul 2026 filing (Kormedi) |
Chung Yeon-woo (elder son) | 386,635 | 0.72 | 29 Jul 2026 |
Kim Eun-mi | 201,550 | 0.38 | 29 Jul 2026 |
Chung Min-woo (younger son) | 25,635 | 0.05 | 29 Jul 2026 |
Kim Joong-hyun (outside director) | 3,179 | 0.01 | 29 Jul 2026 |
Controlling group total | 34,629,568 | 64.47 | 29 Jul 2026 |
Treasury shares | 4,844,216 | 9.02 | H1 FY2026 |
Amorepacific Group | 369,794 (at acquisition) | c. 0.7 | — |
Free float (approx.) | c. 14.2m | c. 26.5 | Derived |
Competitive Landscape
Competitors by Segment
| Business line | Direct competitors (named) | Notes |
|---|---|---|
Dermal fillers / skin boosters | Galderma (Restylane, Sculptra), AbbVie / Allergan Aesthetics (Juvéderm), Merz (Radiesse), LG Chem (YVOIRE), Hugel (The Chaeum / Revolax), Pharma Research (Rejuran), Medytox, Jetema | Caregen differentiates on peptide-added fillers; scale disadvantage |
Hair-loss injectables / cosmeceuticals | Pharma Research (cosmetics), Amorepacific, numerous K-beauty brands | Fragmented |
Cosmetic peptide ingredients | Lubrizol (Lipotec), Croda (Sederma), DSM-Firmenich | Caregen also supplies BASF |
Weight management | Novo Nordisk (Wegovy, oral semaglutide), Eli Lilly (Zepbound, orforglipron pipeline); grey-market "research peptides" | Korglutide sold as a supplement, not a drug; efficacy claims are company-reported |
Glucose management supplements | Generic nutraceuticals (berberine, chromium etc.) | ProGsterol premium pricing cited by Nomura (2024) as a barrier |
Wet AMD | Regeneron/Bayer (Eylea, Eylea HD), Roche (Vabysmo, Lucentis), Novartis (Beovu), aflibercept biosimilars | CG-P5 targets the non-invasive niche |
Aesthetic devices (adjacent KOSDAQ peer) | Classys (HIFU/RF) | Valuation benchmark rather than direct competitor |
Peer Comparison FY2025
| Company | Revenue | Operating income | Operating margin (%) | Revenue growth (%) | R&D / revenue (%) |
|---|---|---|---|---|---|
Caregen | 72.8 | 20.4 | 28.0 | -11.8 | 7.9 |
Pharma Research | 535.7 | 214.2 | 40.0 | — | — |
Hugel | 425.1 | 201.6 | 47.4 | 14.0 | — |
Classys | 336.8 | 170.6 | 50.7 | 38.6 | — |



